PEG-MGF
aka PEGylated Mechano Growth Factor
Mechanism
PEG-MGF is the pegylated form of Mechano Growth Factor (MGF), the distinct 24-amino-acid C-terminal E-peptide encoded by the IGF-1Ec splice variant (IGF-1Eb in rodents) that is transiently upregulated in muscle after mechanical loading or damage. MGF is related to but pharmacologically distinct from mature IGF-1 and IGF-1 LR3. Pegylation extends its half-life from minutes to several hours, and the compound is marketed as a research chemical for muscle repair protocols. It is not FDA-approved for any indication.
Identification
| Sequence | YQPPSTNKNTKSQRRKGSTFEERK |
|---|---|
| Typical dose | 200–400 mcg subcutaneous, 2–3x per week |
| Half-life | ~48–72 hours (vs. ~5–7 minutes for unmodified MGF) |
Vendors selling PEG-MGF
| Vendor | Size | Price | Listed purity | Trust |
|---|---|---|---|---|
| Moglabs | 2 mg | $40.00 | — | 96 |
| BioLongevity Labs | 5 mg | $94.97 | — | 96 |
| Ion Peptide | 2 mg | $39.00 | — | 95 |
| Peptide Tech | 2 mg | $33.99 | — | 94 |
| Peptidology | 5 mg | $87.00 | — | 89 |
| Qihang Peptide | — | — | — | 87 |
| Simple Peptide | 2 mg | $39.00 | — | 85 |
| Peptidegurus | 5 mg | — | — | 84 |
| Crystal Peptides | 2 mg | $49.00 | — | 66 |
| Sports Technology Labs | 2 mg | $46.99 | — | 58 |
| Peptiatlas | — | — | — | 51 |
| HongDa Peptide | — | $91.00 | — | 43 |
| MJT peptides | 2 mg | $97.00 | — | 39 |
| Biotech Peptides | 5 mg | $79.00 | — | — |
| Core Peptides | 5 mg | $63.00 | — | — |
| Flawless Compounds | — | — | — | — |
| Genetic Peptide | 2 mg | $50.00 | — | — |
| Genetic Peptide | 5 mg | $50.00 | — | — |
| Paramount Peptides | 5 mg | $119.00 | — | — |
Research
Performance-enhancing drugs (PEDs) marketed as "research compounds" include unregulated peptides intended to modulate the growth hormone-insulin-like growth factor-1 (GH-IGF-1) axis.
source →The purpose of this study is to assess the efficacy and safety of trontinemab in participants with early symptomatic Alzheimer's disease (AD) (mild cognitive impairment \[MCI\] to mild dementia due to AD).
source →This study is done to find out whether the medicine, semaglutide, has a positive effect on early Alzheimer's disease. Participants will either get semaglutide or placebo (a "dummy" medicine which does not contain any study medicine) - which treatment participants get is decided by an equal chance.
source →We examine a gas-phase approach for converting a subset of amino acid residues in polypeptide cations to dehydroalanine (Dha). Subsequent activation of the modified polypeptide ions gives rise to specific cleavage N-terminal to the Dha residue.
source →This study aims to explore the optimal dose of pegylated recombinant human growth hormone (PEG-rhGH) injection to treat children of Turner syndrome (TS), preliminarily evaluate its safety and efficacy and provide scientific and reliable evidence for the medication dosage in Phase 3 clinical trial.
source →The study was evaluated as the optimal dose for the treatment of SGA short stature children by Pegylated Somatropin, initially evaluated its efficiency and safety for the treatment of SGA short stature children and provided scientific, reliable basis for phase III clinical trials for dose selection.
source →Neurodegeneration is characterized by progressive loss of structure and function of neurons. Several therapeutic methods and drugs are available to alleviate the symptoms of these diseases.
source →This study evaluates the PCSK9 inhibitor, Bococizumab (PF-04950615;RN316), compared to placebo, in reducing the occurrence of major cardiovascular events, including cardiovascular death, myocardial infarction, stroke, and unstable angina requiring urgent revascularization, in high risk subjects who are receiving backgr…
source →The primary purpose of this study is to evaluate the hypothesis that cixutumumab given in combination with cisplatin and pemetrexed is superior to cisplatin and pemetrexed as first-line therapy for patients with advanced nonsquamous non-small cell lung carcinoma (NSCLC).
source →Primary Objective: * To demonstrate the superior efficacy (composite of all-cause death + Myocardial Infarction (MI)) of Otamixaban to Unfractionated Heparin (UFH) + Eptifibatide Secondary Objectives: * To demonstrate the superior efficacy (composite of all-cause death + MI + any stroke) of Otamixaban as compared to UF…
source →The purpose of this clinical research study is to determine whether apixaban is more effective than acetylsalicylic acid in the prevention of strokes associated with patients with atrial fibrillation. The safety of this treatment will also be studied.
source →